Roche obtains EU approval for PERJETA, a new personalised treatment for aggressive type of breast cancer

Roche today announced that the European Medicines Agency (EMA) has approved PERJETA(pertuzumab) for patients with previously untreated HER2-positive metastatic breast cancer (mBC).
Source: Roche Media News - Category: Pharmaceuticals Source Type: news